Research And Markets: The World Market For Asthma/COPD Drugs, Valued At $13.3 Billion In 2003, Is Forecast To Grow To $19.0 Billion By 2009

DUBLIN, Ireland--(BUSINESS WIRE)--Dec. 10, 2004--The world market for asthma/COPD drugs, valued at $13.3 billion in 2003, is forecast to grow to $19.0 billion by 2009, driven by the expansion of combination steroid/bronchodilator products into a wider spectrum of patients, and strong growth in COPD specific therapies.

GlaxoSmithKline and Merck remain the indisputable leaders in asthma, with Pfizer steadily building a presence in COPD.

Research and Markets (http://www.researchandmarkets.com/reports/c10428) has announced the addition of Commercial Insight: Asthma and COPD - Control is the Goal to their offering

The scope of this report is as follows:

-- Outlook for the asthma/COPD market, including key events impacting combination products, leukotriene antagonists, and anticholinergics

-- Global sales forecasts to 2014, including country-specific forecasts for the US, Japan, France, Germany, Italy, Spain and the UK

-- Review of global and country specific opportunities and threats impacting key brands, including Seretide, Symbicort, Singulair, Spiriva, and Daxas

-- Case studies on Seretides promotional strategies on redefining asthma management, and building Xopenexs primary care presence

The highlights of this report are as follows:

-- GSK has added fresh impetus to Seretide growth by focusing on the control of asthma, rather than symptom severity, enabling Seretide to appeal to the full spectrum of patients and move beyond moderate to severe asthma.

-- The growth of Spiriva and Daxas will add breadth to an underdeveloped market and establish Pfizer as the premier company in COPD, which is the fastest growing segment of the market. Landmark morbidity and mortality trials, improved awareness, diagnosis and earlier therapeutic intervention, indicates a very promising outlook for this disease.

-- The dominance of Seretide and Singulair is not likely to be challenged in the foreseeable future, although the large market size, with few NCEs, makes it possible for companies to successfully launch niche products through effective patient targeting.

Reasons to Purchase:

-- Evaluate the expansion of combination products into a wider spectrum of patients through new indications and promotional activities

-- Quantify the future size and scope of the asthma/COPD market and predict the future performance of key compounds

-- Examine the impact of future patent expiries in each of the seven country markets

The contents of this report are as follows:

Chapter 1 Executive Summary

Chapter 2 Market Definition And Overview

Chapter 3 Country Market Assessments

Chapter 5 Commercial Impact And Lifecycle Management: Case Studies

Appendix A - Market Data And Major Brand Key Facts

Appendix B

For more information visit http://www.researchandmarkets.com/reports/c10428